Rifampin isoniazid pyrazinamide: Difference between revisions
No edit summary |
|||
| Line 12: | Line 12: | ||
==US Brand Names== | ==US Brand Names== | ||
Laniazid<sup>®</sup>, Nydrazid<sup>®</sup>, Rifamate<sup>®</sup>, Rifater<sup>®</sup>, Rifinah<sup>®</sup>, Rimactane/INH<sup>®</sup> | Laniazid<sup>®</sup>, Nydrazid<sup>®</sup>, Rifamate<sup>®</sup>, Rifater<sup>®</sup>, Rifinah<sup>®</sup>, Rimactane/INH<sup>®</sup> | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
'''[[Isoniazid description|Description]]''' | '''[[Isoniazid description|Description]]''' | ||
Revision as of 02:01, 30 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Isoniazid, also known as isonicotinylhydrazine (INH), is an organic compound that is the first-line medication in prevention and treatment of tuberculosis. The compound was first synthesized in the early 20th century,[1] but its activity against tuberculosis was first reported in the early 1950s, and three pharmaceutical companies attempted unsuccessfully to simultaneously patent the drug[2] (the most prominent one being Roche, which launched its version, Rimifon, in 1952). The drug was first tested at Many Farms, a Navajo community, due to the Navajo reservation's dire tuberculosis problem and the fact that the population was naïve with respect to streptomycin, the main tuberculosis treatment at the time.[3] With the introduction of isoniazid, a cure for tuberculosis was first considered reasonable.
Category
Antimycobacterial
US Brand Names
Laniazid®, Nydrazid®, Rifamate®, Rifater®, Rifinah®, Rimactane/INH®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages
Mechanisms of Action
References
- ↑ Meyer H, Mally J (1912). "On hydrazine derivatives of pyridine carbonic acids". Monatshefte Chemie verwandte Teile anderer Wissenschaften (in German). 33: 393&ndash, 414. doi:10.1007/BF01517946.PDF fulltext
- ↑ Hans L Riede (2009). "Fourth-generation fluoroquinolones in tuberculosis". Lancet. 373 (9670): 1148&ndash, 1149. doi:10.1016/S0140-6736(09)60559-6. PMID 19345815.
- ↑ Jones, David (2002). "The Health Care Experiments at Many Farms: The Navajo, Tuberculosis, and the Limits of Modern Medicine, 1952-1962". Bulletin of the History of Medicine. 76 (4): 749–790.